MorphoSys (ETR:MOR)‘s stock had its “buy” rating reaffirmed by JPMorgan Chase & Co. in a research note issued to investors on Tuesday.
A number of other equities research analysts also recently weighed in on MOR. Goldman Sachs Group set a €80.00 ($98.77) price target on shares of MorphoSys and gave the company a “neutral” rating in a research report on Monday, November 27th. Independent Research set a €93.00 ($114.81) price target on shares of MorphoSys and gave the company a “buy” rating in a research report on Friday, December 1st. Berenberg Bank set a €85.00 ($104.94) price objective on shares of MorphoSys and gave the company a “buy” rating in a research report on Thursday, December 7th. HSBC set a €64.00 ($79.01) price objective on shares of MorphoSys and gave the company a “sell” rating in a research report on Friday, January 19th. Finally, Royal Bank of Canada set a €57.00 ($70.37) price objective on shares of MorphoSys and gave the company a “sell” rating in a research report on Wednesday, February 14th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and six have issued a buy rating to the company’s stock. MorphoSys currently has a consensus rating of “Hold” and an average price target of €82.30 ($101.60).
Shares of MorphoSys (MOR) opened at €84.80 ($104.69) on Tuesday. MorphoSys has a 1 year low of €49.63 ($61.27) and a 1 year high of €87.35 ($107.84). The firm has a market cap of $2,430.00 and a P/E ratio of -28.75.
COPYRIGHT VIOLATION WARNING: “MorphoSys (MOR) Rating Reiterated by JPMorgan Chase & Co.” was published by American Banking News and is the property of of American Banking News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/03/13/morphosys-mor-rating-reiterated-by-jpmorgan-chase-co.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.